

HR 4455

BIOSIM Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 20, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Sep 23, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4455>

Sponsor

Name: Rep. Schrader, Kurt [D-OR-5]

Party: Democratic • State: OR • Chamber: House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gianforte, Greg [R-MT-At Large]	R · MT		Sep 20, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 23, 2019
Ways and Means Committee	House	Referred to	Sep 20, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 3	Related bill	Sep 8, 2020: Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.

Summary (as of Sep 20, 2019)

Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act

This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.

## Actions Timeline

---

- **Sep 23, 2019:** Referred to the Subcommittee on Health.
- **Sep 20, 2019:** Introduced in House
- **Sep 20, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Sep 20, 2019:** Referred to the Subcommittee on Health.